international registry of present-day cardioversion providing information that is not currently available on country differences and acute and long-term arrhythmia outcome of ECV and PCV.
Methods and results 3940 patients were enrolled, of whom 75% underwent CV. All patients were followed for 2 months. There were large variations concerning mode of CV used, ECV being heterogeneous.
Choice of PCV drug depended on clinical patient profile. Sinus rhythm was restored in 89.7% of patients by ECV and in 69.1% after PCV. Among patients not undergoing CV during admission, 34% spontaneously converted to sinus rhythm within 24 hours. ECV was most successful in patients pretreated with antiarrhythmic drugs (mostly amiodarone). PCV was enhanced by class Ic antiarrhythmic drugs; conversion rate on amiodarone was similar to that seen with rate control drugs. Female patients and those with paroxysmal and first detected AF as well as those without previous ECV responded well to PCV. The median duration of hospital stay was 16.2 and 24.0 hours for ECV and PCV patients, respectively. There were very few CV-related complications regardless of mode of CV. Chronic maintenance of sinus rhythm was enhanced in patients on chronic antiarrhythmic drugs, beta-blockers or inhibitors of the renin-angiotensin system.
Conclusions
Mode of CV varied significantly, but both PCV and ECV were safe and effective. Class Ic drugs were most effective conversion drugs, but amiodarone is used most frequently despite providing merely rate control rather than foreshortening time to conversion. Cardioversion (CV) of AF is critical in alleviating symptoms acutely. Both pharmacological (PCV) (5, 6) and electrical cardioversion (ECV)(7) are widely accepted. PCV (including the "pill-in-the-pocket-approach") is frequently performed in patients with recurrent AF, but caution is needed to avoid complications, such as acute heart failure, bradycardia, and ventricular arrhythmias. (5, (8) (9) (10) ECV is more effective than PCV, especially in persistent AF, but often requires hospitalization, anesthesiology support and greater recovery time. (11) Both are generally safe and effective in producing sinus rhythm acutely. (9) Recommendations, treatments, and goals of rhythm control are clearly given in the guidelines;(2) however, contemporary observational data on cardioversion practices are scarce. (9, (12) (13) (14) The RHYTHM-AF study described clinical routines and outcomes of CV in patients with AF considered for rhythm control. (15) The present paper describes the main study results, focusing on patient characteristics, treatment patterns, and outcomes related to CV from a prospectively collected international multicenter registry.
METHODS

Design and study population
The design of the study has been reported in detail previously.(15) Briefly, RHYTHM-AF is a prospective international multicenter observational study of 3940 patients with AF for whom CV was considered. The protocol did not recommend or discourage any treatments, procedures, or examinations that were not part of routine care. Informed consent was obtained from all patients and the study was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. All data were collected electronically in a central database and follow-up data were collected 60 days after enrollment.
The study was sponsored by Merck & Co., Inc. and its subsidiaries. The Scientific Committee has the authority to make all decisions related to design, conduct, data interpretation and dissemination of study results.
Endpoints
PCV was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Time to sinus rhythm was noted separately. ECV was defined as successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock. We grouped conversion drugs into Vaughan-Williams (16) Class Ic (flecainide, propafenone), and Class III drugs (almost exclusively amiodarone, and sotalol in only 2 instances). Other drugs used for conversion as reported by physicians included almost exclusively the typical rate control drugs (i.e., digitalis, beta-blockers, and verapamil or diltiazem). Figure 2 .
Statistical analysis
RESULTS
Patient characteristics
Overall, CV was successful in 82.6% of the patients. ECV (89.7%) was more successful than PCV (69.1%). Class Ic and class III PCV (amiodarone) was successful in 77%
and 68% of cases, whereas 57% of patients treated by non-antiarrhythmic drugs converted to sinus rhythm. Intravenous and oral PCV were successful in 72% and 63% of patients, respectively.
The increase in the use of class III drugs after cardioversion was significant, mainly due to change in amiodarone prescriptions. There were few complications experienced during the first 5 days after admission, regardless of CV strata (Table II) . Two months after admission, 64.3% of patients were in sinus rhythm. Factors independently associated with successful ECV or PCV and maintenance of sinus rhythm at 2 months follow-up, after multivariate adjustment, are presented in Table III . Drug choice for PCV depended on patient characteristics, with amiodarone mainly used in patients with higher disease burden. Indeed, a relatively high prevalence of CHA 2 DS 2 -VASc score >1 among amiodarone PCVs was observed, compared to all other PCVs.
Specifically the prevalence of heart failure, coronary artery disease and valvular heart disease was relatively high in amiodarone PCVs. A similar disease burden was seen among no CV patients, a potential reason for deferring CV.
In patients with structural heart disease, amiodarone is one of the recommended conversion drugs (2); however, when absent, class Ic drugs are preferred since cardioversion with amiodarone occurs many hours later than with flecainide or propafenone (19) (Figure 4 ).
Despite recommendations, amiodarone and even typical rate control drugs were used in many patients, which may have led to avoidable CV failure, the need for back-up ECVs, and prolonged hospitalisation. Of note, amiodarone performed similarly to rate control drugs, rendering its application for shortening conversion time futile. On the other hand, amiodarone provides acute rate control which is crucial in the wait-and-see approach to CV.
Oral propafenone appeared less effective in producing sinus rhythm than flecainide, perhaps due to the relatively low dose of oral propafenone used. Whereas flecainide was Patients using AAD both at admission and discharge maintained sinus rhythm in the short term (2 months) significantly better than those who were put on these agents only at discharge or who were kept off AAD. In line with recent studies, (20,21) the registry supports the notion that pretreatment and continued antiarrhythmic drug prophylaxis is more effective than other antiarrhythmic drug strategies or no prophylaxis. Additionally, we observed that beta-blockers and inhibitors of the renin-angiotensin system reduced short term recurrences.
Several previous studies have shown that in the presence of amiodarone, angiotensin receptor blockers (ARB) and ACE-inhibitors (ACE-i) help to prevent recurrences after cardioversion both in paroxysmal as well as persistent AF. (2) In the present study, the effect of ACE-i/ARB was independent of continued antiarrhythmic drug use. This may relate to the relatively short term follow-up of 2 months during which mainly subacute recurrences (whose mechanism may differ from that of recurrences occurring later on during follow-up) happen. (11) Aldosterone antagonists have also been reported to reduce recurrences of AF after ECV, (22) but this effect could not be studied since few used these agents in this study. First detected AF was observed to be associated with a worse short term arrhythmia prognosis than persistent AF, for which we do not have an explanation (Table III) . Likewise, it is uncertain why stable angina pectoris or absence of AF symptoms would be associated with better rhythm outcome at 2 months.
This study had several strengths, including its large size, the short period of overall study time enhancing robustness of the data, the standardized collection of data, and the broad scope of patients. It was not without limitations, including lack of full control on representativeness of sites and on consecutiveness of patients as well as a relatively short follow-up period. Nevertheless, it offers insight into the importance of considering patient's preferences concerning mode of CV.
Conclusions
In current practice, pharmacological and electrical cardioversion are safe and effective.
Electrical cardioversion seems well developed, but improvement may be obtained through pharmacological pretreatment. To maximize patients included in the multivariable analysis, for those who had missing B.
